Trials / Completed
CompletedNCT04844918
A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease
Efficacy and Safety of Once-Weekly Tirzepatide in Participants With Obesity Disease: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-J)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 267 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to learn more about tirzepatide in participants with obesity disease. The study will also measure how Tirzepatide affects body weight with a low-calorie diet and increased physical activity. The study will last around 72 Weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tirzepatide | Administered SC |
| OTHER | Placebo | Administered SC |
Timeline
- Start date
- 2021-05-10
- Primary completion
- 2023-06-24
- Completion
- 2023-06-24
- First posted
- 2021-04-14
- Last updated
- 2024-07-16
- Results posted
- 2024-07-16
Locations
18 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04844918. Inclusion in this directory is not an endorsement.